Use of pulsed-wave Doppler echocardiography to measure changes in MPAP. Is further validation required?
Morrell
N W
NW
D000208:Acute Disease; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use; D018619:Echocardiography, Doppler, Pulsed; D006321:Heart / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D000860:Hypoxia / Q000188:drug therapy / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use; D019808:Losartan; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000503:physiopathology; D011651:Pulmonary Artery / Q000000981:diagnostic imaging* / Q000502:physiology; D011660:Pulmonary Heart Disease / Q000188:drug therapy / Q000503:physiopathology; D051381:Rats; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D015203:Reproducibility of Results; D013777:Tetrazoles / Q000627:therapeutic use; D014661:Vasoconstriction / Q000187:drug effects
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; D000804:Angiotensin II; D002216:Captopril; D019808:Losartan